Abstract
To evaluate the effect of priming atracurium over onset time and intubating time of general anesthesia between different genders. Sixty-six male and sixty-four female patients, ASA I-II, aged 18-65 years, were randomly divided into four groups: group M1: male patients with saline priming; group M2: male patients with priming atracurium dose of 0.05 mg/kg; group F1: female patients with saline priming; group F2: female patients with priming atracurium dose of 0.05 mg/kg. General anesthesia was induced with midazolam(0.1 mg*kg(-1)) propofol(0.75 mg*kg(-1)), intubation dose of atracurium (0.5 mg*kg(-1)), fentanyl (3 μg*kg(-1)). The incidences of dizziness, diplopia, heavy eyelids and dyspnea were observed. Neuromuscular tension was quantified by using TOF-Guard neuromuscular monitor, and intubating time was defined as the duration from the infusion of intubation dose of atracurium to the time when T4/T1=0. The intubating time of group F2 was shorter than that of group F1. There was no significant difference between group M1 and group M2. The incidences of dizziness, diplopia and heavy eyelids in group F2 were higher than those in group M2. Atracurium priming technique could shorten the intubation time of female patients, but not for male patients, and the gender plays a key role in affecting the clinical outcome of atracurium priming.
Highlights
Atracurium is one of the non-depolarization neuromuscular blocking agents, and can be used safely for patients with malfunction in liver and kidney owing to its unique degradation of ester hydrolysis and the Hoffman reaction.[1]
We aimed to investigate the different effect of priming atracurium between male and female patients
All patients were randomized into four groups according to the method of random digits generated by SPSS software: group M1: thirty-four male patients, with saline priming; group M2: thirty-two male patients, with atracurium priming (0.05 mg/kg, 1/10 of intubating dose); group F1: thirty-two female patients, with saline priming; group F2: thirty-two female patients, with priming atracurium (0.05 mg/kg, 1/10 of intubating dose)
Summary
Atracurium is one of the non-depolarization neuromuscular blocking agents, and can be used safely for patients with malfunction in liver and kidney owing to its unique degradation of ester hydrolysis and the Hoffman reaction.[1] Its onset time is slower than succinylcholine[2], which limits. 1. Liu Hui, PhD, Department of Anesthesiology, West China Hospital, Sichuan University, Sichuan, 610041, China. Zuo Yunxia, MD, Department of Anesthesiology, West China Hospital, Sichuan University, Sichuan, 610041, China. 1, 2: Department of Anesthesiology, Jiangsu Cancer Hospital, Jiangsu, 210009, China
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
